Table 3

Immunotherapies in development for the treatment of chronic lymphocytic leukemia

TrialAgents investigatedAgent descriptionPrimary outcome for assessment
ZUMA-8 (NCT03624036)brexucabtagene autoleucel for R/R CLLCAR T cellRate of dose-limiting toxicity, ORR
TRANSCEND-CLL-004 (NCT03331198)JCAR017 (lisocabtagene maraleucel) vs JCAR017+ibrutinib for R/R CLLCAR T cell and BTKiRecommended dose, rate of AEs, rate of laboratory abnormalities, CR rate
NCT00774345Lenalidomide vs placebo for maintenance of CLLIMiDOS, PFS
GAIA (NCT02950051)Rituximab-FC+venetoclax vs obinutuzumab+venetoclax vs obinutuzumab+venetoclax+ibrutinib for first-line CLLmAbMRD negativity rate, PFS
GENUINE (NCT02301156)Ublituximab+ibrutinib vs ibrutinibmAbORR, PFS
UNITY-CLL (NCT02612311)Ublituximab+TGR-1202 vs obinutuzumab+chlorambucil vs ublituximab vs TGR-1202 for first-line and R/R CLLmAbPFS
  • AEs, adverse events; BTKi, Bruton’s tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; CR, complete remission; FC, fludarabine, cyclophosphamide; IMiD, immunomodulatory drug; mAb, monoclonal antibody; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R/R, relapsed or refractory.